Premium
Cover Feature: Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines (ChemMedChem 3/2019)
Author(s) -
Buzharevski Antonio,
Paskas Svetlana,
Sárosi MenyhártBotond,
Laube Markus,
Lönnecke Peter,
Neumann Wilma,
Mijatovic Sanja,
MaksimovicIvanic Danijela,
Pietzsch Jens,
HeyHawkins Evamarie
Publication year - 2019
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201900048
Subject(s) - celecoxib , cancer , colorectal cancer , cyclooxygenase , melanoma , chemistry , pharmacology , cancer research , medicine , enzyme , biochemistry
The Cover Feature shows carboranyl analogues of celecoxib, a potent COX‐2‐selective inhibitor (COXIB). Cyclooxygenase‐2 (COX‐2) has a prominent role in the occurrence and progression of various cancers. Recently, there is an expressed focus on the development of new COX‐2‐selective inhibitors (COXIBs) as potential cytostatic agents. A highly stable carborane cluster, which can serve as phenyl mimetic, was implemented in the structure of celecoxib in order to generate analogues with enhanced metabolic stability. Although the new derivatives do not act as COXIBs, they proved to have a potent cytostatic effect on various melanoma and colon cancer cell lines. Cover illustration by Menyhárt‐Botond Sárosi. More information can be found in the Full Paper by Evamarie Hey‐Hawkins et al. on page 315 in Issue 3, 2019 (DOI: 10.1002/cmdc.201800685).